193 related articles for article (PubMed ID: 30224375)
1. UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling.
Dikshit A; Jin YJ; Degan S; Hwang J; Foster MW; Li CY; Zhang JY
Cancer Res; 2018 Nov; 78(22):6462-6472. PubMed ID: 30224375
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
[TBL] [Abstract][Full Text] [Related]
3. Decreased melanoma proliferation and cell survival: turn down your SOX10.
Loftus SK
Pigment Cell Melanoma Res; 2013 Jan; 26(1):3-4. PubMed ID: 23387001
[No Abstract] [Full Text] [Related]
4. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.
Rosenbaum SR; Tiago M; Caksa S; Capparelli C; Purwin TJ; Kumar G; Glasheen M; Pomante D; Kotas D; Chervoneva I; Aplin AE
Cell Rep; 2021 Dec; 37(10):110085. PubMed ID: 34879275
[TBL] [Abstract][Full Text] [Related]
5. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
[TBL] [Abstract][Full Text] [Related]
6. FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms.
Zhang X; Wu J; Luo S; Lechler T; Zhang JY
Oncotarget; 2016 Jun; 7(23):34371-83. PubMed ID: 27144339
[TBL] [Abstract][Full Text] [Related]
7. Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.
Su Z; Zheng X; Zhang X; Wang Y; Zhu S; Lu F; Qu J; Hou L
J Dermatol Sci; 2017 Mar; 85(3):216-225. PubMed ID: 27955842
[TBL] [Abstract][Full Text] [Related]
8. Expression of SOX10, ABCB5 and CD271 in melanocytic lesions and correlation with survival data of patients with melanoma.
Gambichler T; Petig AL; Stockfleth E; Stücker M
Clin Exp Dermatol; 2016 Oct; 41(7):709-16. PubMed ID: 27663144
[TBL] [Abstract][Full Text] [Related]
9. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
10. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma.
Bakos RM; Maier T; Besch R; Mestel DS; Ruzicka T; Sturm RA; Berking C
Exp Dermatol; 2010 Aug; 19(8):e89-94. PubMed ID: 19845757
[TBL] [Abstract][Full Text] [Related]
11. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
12. KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
Riverso M; Montagnani V; Stecca B
Oncogene; 2017 Jun; 36(23):3322-3333. PubMed ID: 28068326
[TBL] [Abstract][Full Text] [Related]
13. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.
Capparelli C; Purwin TJ; Glasheen M; Caksa S; Tiago M; Wilski N; Pomante D; Rosenbaum S; Nguyen MQ; Cai W; Franco-Barraza J; Zheng R; Kumar G; Chervoneva I; Shimada A; Rebecca VW; Snook AE; Hookim K; Xu X; Cukierman E; Herlyn M; Aplin AE
Nat Commun; 2022 Mar; 13(1):1381. PubMed ID: 35296667
[TBL] [Abstract][Full Text] [Related]
14. Identification and functional analysis of SOX10 phosphorylation sites in melanoma.
Cronin JC; Loftus SK; Baxter LL; Swatkoski S; Gucek M; Pavan WJ
PLoS One; 2018; 13(1):e0190834. PubMed ID: 29315345
[TBL] [Abstract][Full Text] [Related]
15. A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas.
Tacha D; Qi W; Ra S; Bremer R; Yu C; Chu J; Hoang L; Robbins B
Arch Pathol Lab Med; 2015 Apr; 139(4):530-6. PubMed ID: 25436903
[TBL] [Abstract][Full Text] [Related]
16. SOX10 expression in superficial spreading and nodular malignant melanomas.
Agnarsdóttir M; Sooman L; Bolander A; Strömberg S; Rexhepaj E; Bergqvist M; Ponten F; Gallagher W; Lennartsson J; Ekman S; Uhlen M; Hedstrand H
Melanoma Res; 2010 Dec; 20(6):468-78. PubMed ID: 20890226
[TBL] [Abstract][Full Text] [Related]
17. SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens.
Mito JK; Conner JR; Hornick JL; Cibas ES; Qian X
Cancer Cytopathol; 2018 Mar; 126(3):179-189. PubMed ID: 29385322
[TBL] [Abstract][Full Text] [Related]
18. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
19. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes.
Seong I; Min HJ; Lee JH; Yeo CY; Kang DM; Oh ES; Hwang ES; Kim J
PLoS One; 2012; 7(2):e31477. PubMed ID: 22363655
[TBL] [Abstract][Full Text] [Related]
20. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
